METTL14 and myelodysplastic syndrome: Moreover, higher METTL14 mRNA level in BM-MNCs of MDS patients was independently associated with shorter survival (P = 0.025, HR = 1.932, 95%CI: 1.086–3.440; Fig. 1L; Supplementary Table 4) and faster leukemic transformation (P = 0.006, HR = 2.320, 95%CI: 1.271–4.233; Fig. 1M; Supplementary Table 5), after adjustment of the IPSS-R, age, gender, mutation status, and treatment therapy.